CoChat

Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies

The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.

Abstract

Background [corrected] Attention-deficit/hyperactivity disorder (ADHD) has been less studied in adults than in children, and the treatment studies reported to date have been small, single-center trials. To assess the efficacy of atomoxetine, a new and highly selective inhibitor of the norepinephrine transporter, we conducted two large, multicenter treatment trials. Methods Two identical studies using randomized, double-blind, placebo-controlled designs and a 10-week treatment period were conducted in adults with DSM-IV-defined ADHD as assessed by clinical history and confirmed by a structured interview (study I, n = 280; study II, n = 256). The primary outcome measure was a comparison of atomoxetine and placebo using repeated measures mixed model analysis of postbaseline values of the Conners' Adult ADHD Rating Scale. Results In each study, atomoxetine was statistically superior to placebo in reducing both inattentive and hyperactive and impulsive symptoms as assessed by primary and secondary measures. Discontinuations for adverse events among atomoxetine patients were under 10% in both studies. Conclusion Atomoxetine appears to be an efficacious treatment for adult ADHD. Its lack of abuse potential may be an advantage for many patients.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0006-3223(02)01671-2

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 44 references

Research works printed but not linked: 1

  1. Heiligenstein J, Spencer T, Faries DE, Biederman J, Kratochvil CJ, Conners CK (2000): Efficacy of atomoxetine vs. placebo in pediatric outpatients with ADHD. Proceedings of the 47th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, October 24–29, New York, NY

Cited by

See all 831

Metadata

Authors
Michelson, D., Adler, L., Spencer, T., Reimherr, F. W., West, S. A., Allen, A. J., Kelsey, D., Wernicke, J., Dietrich, A., & Milton, D.
Affiliations
  • Eli Lilly (United States) (US)
  • New York University (US)
  • Massachusetts General Hospital (US)
  • University of Utah (US)
Corresponding author
Michelson, David
Venue
Biological Psychiatry
Publisher
Elsevier BV
Published
2003-01
Volume
53
Issue
2
Pages
112-120
ISSN
0006-3223 (ISSN-L)
OpenAlex
W2053295943
Cited by
790
References
44
Citations by year
2026: 6 · 2025: 12 · 2024: 14 · 2023: 7 · 2022: 10 · 2021: 6 · 2020: 206 · 2019: 9 · 2018: 6 · 2017: 14 · 2016: 13 · 2015: 24 · 2014: 26 · 2013: 30 · 2012: 36
FWCI
29.99
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Biological Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Keywords
atomoxetine, adult ADHD, norepinephrine transporter inhibitor, ADHD medication, treatment efficacy, inattentive symptoms, adverse events, abuse liability
MeSH terms
Atomoxetine Hydrochloride, Adult, Antidepressive Agents, Attention Deficit Disorder with Hyperactivity, Double-Blind Method, Female, Humans, Male, Propylamines, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. https://app.cochat.ai/papers/10.1016/s0006-3223(02)01671-2
The paper
Michelson, D., Adler, L., Spencer, T., Reimherr, F. W., West, S. A., Allen, A. J., Kelsey, D., Wernicke, J., Dietrich, A., & Milton, D. (2003). Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biological Psychiatry. https://doi.org/10.1016/s0006-3223(02)01671-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.